tiprankstipranks
Trending News
More News >

Fosun Pharma Subsidiary Gains FDA Approval for Novel Alopecia Treatment Trial

Story Highlights
  • Fosun Pharma focuses on innovative drug development in the pharmaceutical industry.
  • FDA approval allows Fosun’s subsidiary to trial a new treatment for androgenetic alopecia.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Fosun Pharma Subsidiary Gains FDA Approval for Novel Alopecia Treatment Trial

Confident Investing Starts Here:

Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an announcement.

Shanghai Fosun Pharmaceutical’s subsidiary, Shanghai MicroH Therapeutics, has received approval from the US FDA to commence a Phase I clinical trial for LBP-ShC4, a live biotherapeutic product aimed at treating androgenetic alopecia. This approval marks a significant step as no live biotherapeutic product has been approved globally for this condition, highlighting the company’s potential impact on the market and its commitment to innovative healthcare solutions.

More about Shanghai Fosun Pharmaceutical (Group) Co

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company based in China, operating in the pharmaceutical industry. The company focuses on the development and production of pharmaceutical products, with a market emphasis on innovative drug development and healthcare services.

Average Trading Volume: 5,778,567

Technical Sentiment Signal: Sell

Current Market Cap: HK$61.89B

Learn more about 2196 stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App